Association of Genetic Polymorphism of ABCG2 Gene and the Occurrence of Oxaliplatin-Induced Peripheral Neuropathy in Patients with Colorectal Cancer DOI Creative Commons

Inas A. Ahmed,

Lamia El Wakeel, Amr Saad

et al.

Archives of Pharmaceutical Sciences Ain Shams University, Journal Year: 2023, Volume and Issue: 7(2), P. 470 - 481

Published: Dec. 1, 2023

Oxaliplatin use in gastrointestinal malignancies is limited by neurotoxicity.This study aims to identify singlenucleotide polymorphisms (SNPs) the ABCG2 gene associated with oxaliplatin-induced peripheral neuropathy (OIPN) Egyptian Colorectal Cancer (CRC) patients treated oxaliplatin-based chemotherapy (CT).All eligible CRC between ages of 18 and 80 participated study, those a neurological illness or condition limiting neurologic function were excluded.On first day every CT cycle, OIPN was assessed scored using National Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v.4.Blood utilized extract genomic DNA detect SNPs (at rs2231137and at rs3114018) High Resolution Melting (HRM) technique followed direct sequencing method melting cluster 3500 genetic analyzers samples selected from each cluster.The occurrence grade 2-3 higher carrying G/G genotype (rs2231137) than G/A same locus (96.7% versus 82.0%; P= 0.05).While, not significantly different genotypes (C/C, A/C, A/A) rs3114018 (92.9%, 82.1% 80.0% respectively; 0.309).In conclusion, among more allele (rs2231137).While, similarly this patient population.

Language: Английский

Colorectal cancer DOI
Cathy Eng, Takayuki Yoshino, Érika Ruiz-García

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10449), P. 294 - 310

Published: June 20, 2024

Language: Английский

Citations

57
Irinotecan-induced dysarthria and management DOI Creative Commons

Dennis Marjoncu,

Kerri Jones

Journal of Oncology Pharmacy Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Irinotecan is chemotherapeutic agent often used in abdominal cancers such as colorectal and pancreatic cancers. While associated with non-central nervous system (CNS) adverse effects, rare cases it may present paresthesias dysarthrias. In one case, a patient received an irinotecan-containing regimen (fluorouracil, irinotecan, oxaliplatin) experienced several neurotoxic which was successfully managed. A female newly-diagnosed cancer started on fluorouracil, oxaliplatin (modified FOLFIRINOX). She developed dysarthrias early the course. Causality assessment conducted via Naranjo criteria, yielding score of 6, indicating probable reaction. Initially managed steroids lorazepam, she eventually given prophylactic strategy atropine 0.4 mg longer infusion time 3 h instead 90 min needed lorazepam. This alleviated able to complete 12 cycles therapy, resulting partial response at end treatment. Prolonging giving help prevent these effects irinotecan.

Language: Английский

Citations

1
Drug delivery for platinum therapeutics DOI
Hui Liu, Jiahui Zou, Xiaotong Li

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 503 - 523

Published: Feb. 11, 2025

Language: Английский

Citations

0
Picropodophyllin, an IGF‑1 receptor inhibitor, enhances oxaliplatin efficacy in chemoresistant colorectal cancer HCT116 cells by reducing metastatic potential DOI Open Access
Nurçin Kayacık, Hasan Kurter, Tolga Sever

et al.

Oncology Letters, Journal Year: 2025, Volume and Issue: 29(5), P. 1 - 12

Published: March 6, 2025

The insulin‑like growth factor receptor (IGF‑1R) axis drives cellular growth, survival and chemoresistance in colorectal cancer (CRC) by promoting proliferative signaling, anti‑apoptotic effects epithelial‑mesenchymal transition (EMT). Targeting the IGF‑1R pathway is therefore a promising strategy, not only for overcoming drug resistance, but also reducing migration metastatic behavior related to EMT. present study aimed evaluate potential of picropodophyllin (PPP), selective inhibitor, enhance oxaliplatin (OX) HCT116 OX‑resistant HCT116‑R cells. Cell viability was evaluated using resazurin‑based assay following 48‑h combination treatment with OX at its IC50 concentrations (HCT116 cells, 53 µM 324 µM) PPP (1 µM). Migration assessed wound healing assays, images captured analyzed 0 48 h. Additionally, immunofluorescence staining performed assess E‑cadherin vimentin expression, evaluating epithelial mesenchymal characteristics. In (53 significantly reduced cell 0.65‑fold compared alone (P=0.0286). Wound assays demonstrated that combining decreased migration, 0.34‑fold 0.22‑fold reductions, respectively (P<0.05). Immunofluorescence revealed this increased 1.37‑ 1.63‑fold, (P<0.05), indicating role enhancing characteristics EMT‑related resistance. These findings highlight cytotoxic anti‑metastatic chemo‑resistant CRC thus offering strategy resistance improving patient outcomes treatment.

Language: Английский

Citations

0
Microbiome as a predictive biomarker in locally advanced rectal cancer DOI Open Access

N. Mulet Margalef,

Berta Martín, Eva Martinez‐Balibrea

et al.

Microbiome Research Reports, Journal Year: 2025, Volume and Issue: 4(2)

Published: March 24, 2025

The incidence of locally advanced rectal cancer (LARC) among young people is rising alarmingly. In recent years, new protocols have been introduced for the management LARC, some which are associated with risk significant toxicity. Despite these advancements, robust predictive biomarkers LARC yet to be established. microbiome has emerged as a potential biomarker due its interaction tumor multiomics. This article provides critical overview current evidence on and including relationship immune system epigenomics, also highlights both limitations future perspectives in field.

Language: Английский

Citations

0
A Case Study on Complete Pathological Response in Advanced Rectal Cancer Patient with Oxaliplatin-based Chemotherapy without Cumulative Neurotoxicity DOI

Rehab A. M Jawad,

Bahir Abdul Razzaq Mshimesh, Qasim S. Al‐Mayah

et al.

Journal of Gastrointestinal Cancer, Journal Year: 2025, Volume and Issue: 56(1)

Published: April 16, 2025

Language: Английский

Citations

0
Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology DOI Creative Commons
Daniel Ejim Uti, Item Justin Atangwho, Esther Ugo Alum

et al.

Discover Nano, Journal Year: 2025, Volume and Issue: 20(1)

Published: April 24, 2025

Cancer treatments often exploit oxidative stress to selectively kill tumour cells by disrupting their lipid peroxidation membranes and inhibiting antioxidant enzymes. However, plays a dual role in cancer progression, acting as both promoter suppressor. Balancing through therapy remains challenge, excessive activity may compromise the efficacy of chemotherapy radiotherapy. This review explores antioxidants mitigating while maintaining treatment efficacy. It highlights recent advancements nanotechnology-based targeted delivery optimize therapeutic outcomes. A comprehensive literature was conducted using reputable databases, including PubMed, Scopus, Web Science, ScienceDirect. The search focused on publications from past five years (2020-2025), supplemented relevant studies earlier years. Keywords such "antioxidants," "lipid peroxidation," "nanotechnology therapy," "oxidative stress" were utilized. Relevant articles critically analysed, graphical illustrations created. Emerging evidence suggests that nanoparticles, liposomes, polymeric metal-organic frameworks, others, can effectively encapsulate control release minimizing systemic toxicity. Stimuli-responsive carriers with tumour-specific targeting mechanisms further enhance delivery. Studies indicate these strategies help preserve normal cells, mitigate stress-related damage, improve challenges bioavailability, stability, potential interactions standard therapies remain. Integrating nanotechnology antioxidant-based interventions presents promising approach for optimizing therapy. Future research should focus refining modulation strategies, assessing profiles during treatment, employing biomarkers determine optimal dosing. balanced use adverse effects.

Language: Английский

Citations

0
Endothelial Glycocalyx in the Peripheral Capillaries is Injured Under Oxaliplatin-Induced Neuropathy DOI Creative Commons

Takahiro Kuroda,

Akio Suzuki, Hideshi Okada

et al.

Journal of Pain, Journal Year: 2024, Volume and Issue: 25(6), P. 104462 - 104462

Published: Jan. 10, 2024

Oxaliplatin, a platinum-based anticancer drug, is associated with peripheral neuropathy (oxaliplatin-induced neuropathy, OIPN), which can lead to worsening of quality life and treatment interruption. The endothelial glycocalyx, fragile carbohydrate-rich layer covering the luminal surface cells, acts as an gatekeeper has been suggested protect nerves, astrocytes, other cells from toxins substances released capillary vessels. Mechanisms underlying OIPN role glycocalyx remain unclear. This study aimed define changes in three-dimensional ultrastructure near nerve fibers hind paws mice OIPN. mouse model OPIN revealed disruption compartment, accompanied by vascular permeability, edema, damage nerves. To investigate potential interventions, nafamostat mesilate, protective agent was used tumor-bearing male mice. Nafamostat mesilate suppressed mechanical allodynia neuropathy. It also prevented intra-epidermal fiber loss improved permeability paws. capillaries that lie within bundles novel finding OPIN. Furthermore, these findings point toward new strategy targeting prevent injury effective well many diseases. PERSPECTIVE: damages capillaries, increasing permeability. In order OIPN, this work offers therapy approach targets glycocalyx.

Language: Английский

Citations

2
An Emerging Aspect of Cancer Neuroscience: A Literature Review on Chemotherapy-induced Peripheral Neuropathy DOI Creative Commons
Zhenxing Tao, Zhiqin Chen, Xiaochen Zeng

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 611, P. 217433 - 217433

Published: Dec. 28, 2024

The nervous system governs both ontogeny and oncology. Foundational discoveries have clarified the direct communication of neurotransmitters with tumors indirect interactions through neural effects on immune tumor microenvironment. Meantime, is susceptible to cancer its treatment. Chemotherapy-induced peripheral neuropathy (CIPN) most common side that significantly reduce efficacy anti-cancer treatment patients' quality life by leading dose reduction or early cessation chemotherapy. However, there are no effective strategies reverse treat CIPN. A better understanding mechanisms expected enable development next generation therapies. Here, we summarize recent important studies clinical manifestations, risk factors, prediction, pathogenesis, prevention, We also provide perspectives insights regarding rationales bidirectional between system.

Language: Английский

Citations

2
WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis DOI Creative Commons

Yue‐Tao Tan,

Ting Li,

Ruo-Bing Wang

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 604, P. 217254 - 217254

Published: Sept. 12, 2024

Language: Английский

Citations

1